

# Press Release

Lund, SWEDEN – April 30, 2009

## Press release from the 2009 Annual General Meeting of Hansa Medical AB

**The following resolutions were passed at Hansa Medical's Annual General Meeting held in Malmö on April 29, 2009:**

The Meeting adopted the income statement, balance sheet, consolidated income statement and consolidated balance sheet and resolved that no dividend shall be paid for the 2008 financial year.

The Meeting resolved to re-elect Bo Håkansson, Per Belfrage and Stina Gestrelus to the Board of Directors. Bo Håkansson was re-elected as Chairman of the Board. For the period until the next Annual General Meeting, Board fees totaling SEK 80,000 shall be paid to the Chairman of the Board and SEK 60,000 to each of the other Board members. The Meeting also resolved that auditors' fees shall be paid in accordance with approved invoices.

The Meeting resolved to amend the Articles of Association in accordance with the following. The company's registered office was changed from Malmö to Lund. The limits for the company's share capital were changed from not less than SEK 10,000,000 and not more than SEK 40,000,000 to not less than SEK 19,000,000 kronor and not more than SEK 76,000,000. The limits for the number of shares were changed from not fewer than 2,000,000 and not more than 8,000,000 to not fewer than 3,800,000 and not more than 15,200,000. The provision pertaining to the locations where General Meetings of Shareholders may be held was changed so that such meetings may be held in Lund or Stockholm instead of Malmö or Stockholm.

The Meeting authorized the Board for the period until the next Annual General Meeting to make decisions to increase the company's share capital by not more than SEK 50,000,000 through new issues of not more than 10,000,000 shares. The Board shall be entitled to make decisions concerning cash issues, non-cash issues or issues offsetting debt, with or without disapplying the shareholders' preferential rights. In the event of a deviation, the reason for the deviation must be to broaden the company's ownership structure or to raise development capital.

The complete resolutions and minutes of the Meeting are available in Swedish from the company in Lund and will be sent to shareholders who so request.

For more information, please contact:

**Emanuel Björne, CEO**

Mobile: +46 707 17 54 77

E-mail: [emanuel.bjorne@hansamedical.com](mailto:emanuel.bjorne@hansamedical.com)

### ABOUT HANSA MEDICAL

Hansa Medical refines biomedical discoveries into candidate drugs and diagnostic analytical methods. The company's long-term goal is to bring new products to market through collaboration agreements with pharmaceutical and diagnostics companies. Hansa Medical's lead project, IdeS, is an innovative drug for treatment in conjunction with organ transplantation and autoimmune disease. The company also pursues other development projects, including antibody-based treatment of rheumatoid arthritis and diagnostics and drugs for sepsis.

Hansa Medical AB  
P.O. Box 785  
SE-220 07 Lund, SWEDEN  
TELEPHONE +46 46 16 56 70  
FAX +46 46 12 77 75  
[info@hansamedical.com](mailto:info@hansamedical.com)  
[www.hansamedical.com](http://www.hansamedical.com)

VISITING ADDRESS:  
Scheelevägen 22  
Lund, SWEDEN